Brief: Alvotech Says It Will Manufacture Its High-Concentration Interchangeable Biosimilar To Humira For Quallent Pharmaceuticals

Alvotech SA

30/04/2024 09:03

April 30 (Reuters) - Alvotech SA  ALVO.O :
    * U.S. COMMERCIALIZATION AGREEMENT WITH QUALLENT TO DRIVE
PATIENT
SAVINGS WITH FIRST HIGH-CONCENTRATION CITRATE-FREE
INTERCHANGEABLE BIOSIMILAR TO HUMIRA® (ADALIMUMAB)
    * ALVOTECH SA - ALVOTECH WILL MANUFACTURE ITS
HIGH-CONCENTRATION
INTERCHANGEABLE BIOSIMILAR TO HUMIRA(®) (ADALIMUMAB) FOR
QUALLENT PHARMACEUTICALS
    * ALVOTECH SA - STRATEGIC AGREEMENT IS IN ALIGNMENT WITH
ALVOTECH'S U.S. COMMERCIALIZATION AGREEMENT WITH TEVA
PHARMACEUTICALS

Source text for Eikon:  ID:nGNX9Hh2Y1 
Further company coverage:  ALVO.O 

 ((Reuters.Briefs@thomsonreuters.com;))